Vol 1. No. 1 (Published)

Published: 2015-06-30

Editorial

A Foreword from the Editor

Jean-Marie Boeynaems

1-2
- PDF

Review Article

Models for accessing biomedical innovation in Asia

Young-Hwa Kim, Ajay Gautam

3-9
- PDF
Philanthropies as partners for drug development in public–private partnerships

Mark D. Lim, Martha A. Brumfield, Michel Goldman

10-13
- PDF
TransCelerate: a global collaboration across biopharmaceutical R&D to accelerate and simplify new medi-cines development

Lynn Marks

14-19
- PDF
The European lead factory—an experiment in collaborative drug discovery

Hugh Laverty, Kristina Maria Orrling, Fabrizio Giordanetto, Magali Poinot, Eckhard Ottow, Ton Wilhelmus Rijnders, Dimitrios Tzalis, Stefan Jaroch

20-33
- PDF
The Predictive Safety Testing Consortium: safety bio-markers, collaboration, and qualification

John-Michael Sauer, Elizabeth G Walker, Amy C Porter

34-45
- PDF
Open innovation to bolster research and development for neglected and emerging infectious diseases

Jennifer Dent, Katy M Graef, Paddy Shivanand

46-50
- PDF
Critical Path to Tuberculosis Drug Regimens: Global collaboration to accelerate development of novel drug regimens and rapid drug susceptibility tests for tuberculosis

Debra Hanna, Marco Schito, Klaus Romero

51-58
- PDF
A systems approach to enhance clinical research and medicines development

Honorio Silva, Greg Koski, Matthew Whalen, Mary Tobin, Beat Widler, Al O. Pacino II, Brian Edwards

59-67
- PDF
European initiatives for better training in medicines development

Mike Hardman

68-73
- PDF
EUPATI: Collaboration between patients, academia and industry to champion the informed patient in the research and development of medicines

Daphnee S Pushparajah, Jan Geissler, Niels Westergaard

74-80
- PDF